SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 13, 2002 US ONCOLOGY, INC. ----------------------------- (Exact Name of Registrant as Specified in its Charter) Delaware 0-26190 84-1213501 - ---------------- ------------ ------------------- (State or Other (Commission (I.R.S.Employer Jurisdiction of File Number) Identification No.) Incorporation or Organization) 16825 Northchase Drive, Suite 1300 Houston, Texas 77060 -------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: (832) 601-8766 Item 9. REGULATION FD DISCLOSURE On August 13, 2002, R. Dale Ross, Chairman of the Board and Chief Executive Officer of US Oncology, Inc. (the "Corporation"), and Bruce D. Broussard, Chief Financial Officer of the Corporation, each filed with the Securities and Exchange Commission (the "SEC") a statement under oath regarding facts and circumstances relating to the Securities Exchange Act filings of the Corporation, as required by the SEC's Order Requiring the Filing of Sworn Statements Pursuant to Section 21(a)(1) ofthe Securities Exchange Act of 1934 (File No. 4-460, June 27, 2002). The statements are attached to this report as exhibits. Item 7. FINANCIAL STATEMENTS AND EXHIBITS c) Exhibits 99.1 STATEMENT UNDER OATH OF CHIEF EXECUTIVE OFFICER REGARDING FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS 99.2 STATEMENT UNDER OATH OF CHIEF FINANCIAL OFFICER REGARDING FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934,the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 13, 2002 US ONCOLOGY, INC. By: Bruce D. Broussard ------------------------- Bruce D. Broussard Chief Financial Officer